Table 8.
Association of MMP2 rs2285053 (−735 C/T) SNP with the age of disease onset and MoCA score.
| Phenotype | Patient Group | Genotypes | Best Model | p-Value | ||
|---|---|---|---|---|---|---|
| CC | CT | TT | ||||
| AOO | Whole | 76.85 ± 6.29 | 78.10 ± 5.84 | 78.00 ± 0.00 | Dominant | 0.18 * |
| APOE ε4 + | 75.81 ± 5.44 | 76.32 ± 5.76 | 78.00 ± 0.00 | Dominant | 0.67 † | |
| APOE ε4 − | 77.62 ± 6.79 | 79.37 ± 5.64 | - | Dominant | 0.18 † | |
| MoCA | Whole | 15.49 ± 6.08 | 15.29 ± 5.62 | 23.00 ± 0.00 | Dominant | 0.96 ‡ |
| APOE ε4 + | 15.59 ± 5.60 | 15.24 ± 5.92 | 23.00 ± 0.00 | Dominant | 0.95 $ | |
| APOE ε4 − | 15.42 ± 6.44 | 15.31 ± 5.56 | - | Dominant | 0.95 $ | |
Age at onset (AOO) and Montreal Cognitive Assessment (MoCA) are presented as the mean and standard deviation. The “−” sign means absence of the APOE ε4 allele, while the “+” sign denotes the presence of one or two APOE ε4 allele copies. Linear regression analysis was adjusted for * sex and APOE ε4 carrier status; † sex; ‡ age, sex, disease duration, and ApoE ε4 carrier status; $ age, sex, and disease duration.